专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US08848569B2 Method and device for power control in non-adaptive retransmission 有权
标题翻译：非自适应重传中功率控制的方法和装置
公开(公告)号：US08848569B2
公开(公告)日：2014-09-30
申请号：US13576397
申请日：2010-05-17
申请人： Lin Wang , Peng Zhang , Liping Wang
发明人： Lin Wang , Peng Zhang , Liping Wang
IPC分类号： H04L1/00 , H04W4/00 , G08C17/00
CPC分类号： H04L1/1822 , H04W52/20 , H04W52/221 , H04W52/362 , H04W52/48
摘要： The disclosure discloses a method and device for power control in non-adaptive retransmission. The solution thereof includes: when UE does not obtain a TPC adjustment value of a current HARQ process by parsing, determining a current power control mode; if the mode is an accumulation mode, determining whether the calculated sum of TPC adjustment values of each HARQ process is smaller than a given threshold, if yes, obtaining a transmission power by adding an increment adjustment value to a retransmission power, otherwise, calculating the transmission power of UE according to a formula in a protocol; if the mode is an absolute value mode, obtaining a transmission power by adding an increment adjustment value to a retransmission power. The solution can improve the SINR detected by an eNB and improve a retransmission success rate, thereby saving radio resources, facilitating utilization of radio resources and reduction of transmission delay, improving the throughput rate of an LTE system and improving the system performance.
摘要翻译：本公开公开了一种用于非自适应重传中的功率控制的方法和装置。其解决方案包括：当UE不通过解析获得当前HARQ进程的TPC调整值时，确定当前功率控制模式; 如果模式是累加模式，则确定所计算的每个HARQ过程的TPC调整值的和是否小于给定阈值，如果是，则通过将增量调整值与重发功率相加来获得发送功率，否则，计算 UE根据协议中的公式发送功率; 如果模式是绝对值模式，则通过将增量调整值与重发功率相加来获得发送功率。该方案可以提高基站检测到的SINR，提高重发成功率，节省无线资源，便于利用无线资源，减少传输延迟，提高LTE系统吞吐率，提高系统性能。

22. 发明授权

US08247415B2 Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists 有权
标题翻译：羟基甲基吡咯烷作为3肾上腺素能受体激动剂
公开(公告)号：US08247415B2
公开(公告)日：2012-08-21
申请号：US12417239
申请日：2009-04-02
申请人： Richard Berger , Lehua Chang , Scott D. Edmondson , Stephen D. Goble , Sookhee Nicole Ha , Nam Fung Kar , Ihor E. Kopka , Bing Li , Gregori J. Morriello , Chris R. Moyes , Dong-Ming Shen , Liping Wang , Cheng Zhu
发明人： Richard Berger , Lehua Chang , Scott D. Edmondson , Stephen D. Goble , Sookhee Nicole Ha , Nam Fung Kar , Ihor E. Kopka , Bing Li , Gregori J. Morriello , Chris R. Moyes , Dong-Ming Shen , Liping Wang , Cheng Zhu
IPC分类号： C07D237/30 , C07D239/90 , C07D221/02 , C07D277/60 , A61K31/502 , A61K31/517 , A61K31/435 , A61K31/428 , A61P13/10 , A61P13/06
CPC分类号： C07D487/04 , C07D401/12 , C07D403/12 , C07D417/12 , C07D471/04
摘要： The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
摘要翻译：本发明提供式（I）化合物，其药物组合物及其用于治疗或预防由β-肾上腺素能受体激活介导的疾病的方法。

23. 发明申请

US20120157432A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS 有权
公开(公告)号：US20120157432A1
公开(公告)日：2012-06-21
申请号：US13392662
申请日：2010-08-17
申请人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent j. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu
发明人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent j. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu
IPC分类号： A61K31/4025 , A61K31/4155 , C07D403/12 , A61K31/497 , C07D413/14 , A61K31/4245 , C07D209/96 , A61K31/407 , C07D401/14 , A61K31/4439 , C07D487/04 , A61K31/519 , C07D401/12 , A61K31/454 , C07D221/20 , A61K31/438 , A61K31/4545 , C07D265/12 , A61K31/536 , A61K31/501 , A61K31/496 , A61P13/02 , C07D403/14
CPC分类号： C07D403/14 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/147 , C07D491/20 , C07D495/10 , C07D495/20 , C07D497/10 , C07D498/04 , C07D513/04 , C07D513/20
摘要： The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

24. 发明申请

US20120093779A1 COMPLEX MICROBIAL PREPARATION FOR TREATING DIABETES AND PREPARATIVE METHOD AND USE THEREOF 审中-公开
标题翻译：用于治疗糖尿病的复杂微生物制剂及其制备方法及其用途
公开(公告)号：US20120093779A1
公开(公告)日：2012-04-19
申请号：US13257368
申请日：2010-11-03
申请人： Liping Wang
发明人： Liping Wang
IPC分类号： A61K35/74 , A61P3/10
CPC分类号： A61K35/74 , A61K35/742 , A61K35/747 , A61K36/06 , A61K36/064 , A61K2035/115 , C12N1/18 , C12N1/20 , A61K2300/00
摘要： A complex microbial preparation comprises (in vol. %): Photosynthetic bacterium (5-15%), Bacillus (10-20%), Yeasts (20-35%), Lactobacillus (30-45%) and Actinomycetes (3-10%). The preparative method of the complex microbial preparation involves first and second level complex fermentations. The first level complex fermentation involves: (a) separately inoculating the above-mentioned bacteria on first level culture media and culturing to obtain first level bacteria, (b) separately inoculating the obtained first level bacteria on second level culture media and culturing to obtain fermenting bacterial liquids, (c) mixing the five obtained fermenting bacterial liquids to obtain first level compound bacteria. The second level complex fermentation involves: adding sterile water, Lactobacillus plantarum, Lactobacillus acidophilus, Saccharomyces cerevisiae and brown sugar to the obtained first level compound bacteria, mixing uniformly in a same fermentor, and culturing to obtain second level complex microbial preparation. The complex microbial preparation is used in treatment for diabetes.
摘要翻译：复合微生物制剂包含（体积％）：光合细菌（5-15％），芽孢杆菌属（10-20％），酵母菌（20-35％），乳杆菌属（30-45％）和放线菌％）。复杂微生物制剂的制备方法涉及第一和第二级复合发酵。第一级复合发酵包括：（a）在第一级培养基上分别接种上述细菌并培养以获得一级细菌，（b）将获得的一级细菌分别接种在二级培养基上并培养以获得发酵细菌液体，（c）混合五种获得的发酵细菌液体以获得一级复合细菌。第二级复合发酵涉及：将无菌水，植物乳杆菌，嗜酸乳杆菌，酿酒酵母和红糖加入到所得一级复合菌中，在相同的发酵罐中均匀混合，培养获得二级复合微生物制剂。复杂的微生物制剂用于治疗糖尿病。

25. 发明授权

US07388019B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 有权
标题翻译： 3-氨基-4-苯基丁酸衍生物作为二肽基肽酶抑制剂，用于治疗或预防糖尿病
公开(公告)号：US07388019B2
公开(公告)日：2008-06-17
申请号：US10542694
申请日：2004-01-27
申请人： Wallace T. Ashton , Charles G. Caldwell , Joseph L. Duffy , Robert J. Mathvink , Liping Wang , Ann E. Weber
发明人： Wallace T. Ashton , Charles G. Caldwell , Joseph L. Duffy , Robert J. Mathvink , Liping Wang , Ann E. Weber
IPC分类号： C07D471/04 , A61K31/4375 , A61P3/10 , C07D487/04 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61K31/53
CPC分类号： C07D471/04 , C07D217/06 , C07D217/26
摘要： The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
摘要翻译：本发明涉及作为二肽基肽酶-IV酶（“DP-IV抑制剂”）的抑制剂的3-氨基-4-苯基丁酸衍生物，其可用于治疗或预防其中二肽基肽酶 - 涉及IV酶，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及二肽基肽酶-IV酶的疾病中的用途。

26. 发明授权

US6140349A Cyclic amine modulators of chemokine receptor activity 失效
标题翻译：趋化因子受体活性的环胺调节剂
公开(公告)号：US6140349A
公开(公告)日：2000-10-31
申请号：US241486
申请日：1999-02-01
申请人： Charles G. Caldwell , Malcolm Maccoss , Paul E. Finke , Sander G. Mills , Bryan Oates , Shankaran Kothandaraman , Dooseop Kim , Liping Wang
发明人： Charles G. Caldwell , Malcolm Maccoss , Paul E. Finke , Sander G. Mills , Bryan Oates , Shankaran Kothandaraman , Dooseop Kim , Liping Wang
IPC分类号： C07D211/56 , C07D211/58 , C07D401/06 , C07D405/06 , C07D409/06 , C07D521/00 , A61K31/445 , C07D409/10
CPC分类号： C07D231/12 , C07D211/56 , C07D211/58 , C07D233/56 , C07D249/08 , C07D401/06 , C07D405/06 , C07D409/06
摘要： The present invention is directed to cyclic amines of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
摘要翻译：本发明涉及式I的环胺（其中R1，R2，R3，m和n如本文所定义），其可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-1，CCR-2，CCR-2A，CCR-2B，CCR-3，CCR-4，CCR-5，CXCR-3和/或CXCR- 4。

27. 发明申请

US20160060256A1 THIAZOLE-SUBSTITUTED AMINOPYRIMIDINES AS SPLEEN TYROSINE KINASE INHIBITORS 有权
标题翻译：噻唑替代氨基嘧啶作为分离型酪氨酸激酶抑制剂
公开(公告)号：US20160060256A1
公开(公告)日：2016-03-03
申请号：US14786466
申请日：2014-04-22
申请人： Kenneth L. ARRINGTON , Byron DUBOIS , John S. DEBENHAM , Ping LIU , Alan B. NORTHRUP , Jason W. SZEWCZYK , Liping WANG , Ming WANG , MERCK SHARP & DOHME CORP.
发明人： Kenneth L. Arrington , Byron DuBois , John S. Debenham , Ping Liu , Alan B. Northrup , Jason W. Szewczyk , Liping Wang , Ming Wang
IPC分类号： C07D417/14 , C07D417/12 , A61K31/5377 , A61K31/506
CPC分类号： C07D417/14 , A61K31/427 , A61K31/506 , A61K31/5377 , C07D417/12
摘要： The invention provides certain thiazole-substituted aminopyrimidine compounds of the Formula (I) (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, and the subscripts r, s, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
摘要翻译：本发明提供了式（I）（I）的某些噻唑取代的氨基嘧啶化合物或其药学上可接受的盐，其中R1，R2，R3，R5，R6和下标r，s和t如本文所定义。本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或病症的方法。

28. 发明申请

US20160060255A1 THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS 有权
标题翻译：噻唑替代氨基酸作为分离型酪氨酸激酶抑制剂
公开(公告)号：US20160060255A1
公开(公告)日：2016-03-03
申请号：US14786464
申请日：2014-04-22
申请人： Neville J. ANTHONY , Brain M. ANDERSEN , Alan B. NORTHRUP , Kaleen K. CHILDERS , Anthony FRIO , Thomas A. MILLER , Yuan LIU , Michelle R. MACHACEK , Hyun Chong WOO , Kerrie B. SPENCER , John Michael ELLIS , Micheal D. ALTMAN , Eric T. ROMEO , Daniel GUAY , Jonathan GRIMM , Marie-Eve LEBRUN , Joel S. ROBICHAUD , Liping WANG , Byron DUBOIS , Qiaolin DENG , MERICK SHARP & DOHNE CORP. , MERCK CANADA INC.
发明人： Neville J. Anthony , Brian M. Andresen , Alan B. Northrup , Kaleen K. Childers , Anthony Donofrio , Thomas A. Miller , Yuan Liu , Michelle R. Machacek , Hyun Chong Woo , Kerrie B. Spencer , John Michael Ellis , Michael D. Altman , Eric T. Romeo , Daniel Guay , Jonathan Grimm , Marie-Eve Lebrun , Joel S. Robichaud , Liping Wang , Byron DuBois , Qiaolin Deng
IPC分类号： C07D417/14 , A61K31/53 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K31/497
CPC分类号： C07D417/14 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/53 , C07D417/12
摘要： The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4, and R4 are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).
摘要翻译：本发明提供式（I）的某些噻唑取代的氨基杂芳基化合物或其药学上可接受的盐，其中X 1，X 2，X 3，X 4，Y 1，Y 2，Y 3，Y 4和R 4如本文所定义。本发明还提供包含这些化合物的药物组合物，以及使用该化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或病症的方法。

29. 发明授权

US08764941B2 Base paper of aramid fiber honeycomb core and manufacturing method thereof 有权
标题翻译：芳纶纤维蜂窝芯基纸及其制造方法
公开(公告)号：US08764941B2
公开(公告)日：2014-07-01
申请号：US13055293
申请日：2009-07-21
申请人： Peizhi Heng , Wenyong Tang , Shiyi Tao , Liping Wang
发明人： Peizhi Heng , Wenyong Tang , Shiyi Tao , Liping Wang
IPC分类号： D21H13/26 , D21H13/24 , D21H25/04
CPC分类号： D21H13/26 , D21H13/24 , D21H25/04 , Y10T428/24149
摘要： A base paper of aramid fiber honeycomb core and its manufacturing method are provided. The base paper comprises 11-90 parts by weight of structural fiber, 10-70 parts by weight of crosslinking fiber, and 0-19 parts by weight of additive fiber, wherein the structural fiber is poly(p-phenylene terephthal amide) fiber, the crosslinking fiber is poly(m-phenylene isophthal amide) fibrid, and the additive is polyester fiber.
摘要翻译：提供了芳纶纤维蜂窝芯的原纸及其制造方法。原纸包含11-90重量份的结构纤维，10-70重量份的交联纤维和0-19重量份的添加剂纤维，其中结构纤维是聚（对苯二甲酰对苯二胺）纤维，交联纤维是聚（间亚苯基间苯二甲酰胺）纤条体，添加剂是聚酯纤维。

30. 发明申请

US20140100250A1 PYRIDYL AMINOPYRIDINES AS SYK INHIBITORS 有权
标题翻译：吡啶氨基酰胺作为SYK抑制剂
公开(公告)号：US20140100250A1
公开(公告)日：2014-04-10
申请号：US14116205
申请日：2012-05-04
申请人： Michael D. Altman , Maria Emilia Di Francesco , Andrew M. Haidle , Ryan D. Otte , John Michael Ellis , Kaleen Konrad Childers , Alan B. Northrup , Liping Wang
发明人： Michael D. Altman , Maria Emilia Di Francesco , Andrew M. Haidle , Ryan D. Otte , John Michael Ellis , Kaleen Konrad Childers , Alan B. Northrup , Liping Wang
IPC分类号： C07D417/14
CPC分类号： C07D417/14
摘要： The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.
摘要翻译：本发明提供了式I的新型嘧啶胺，其是脾脏酪氨酸激酶的有效抑制剂，并且可用于治疗和预防由所述酶介导的疾病，例如哮喘，COPD，类风湿性关节炎和癌症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式